Today, the Food and Drug Administration approved Opill – the first-ever daily oral contraceptive approved in the U.S. to prevent pregnancy without a prescription. Perrigo, which sought FDA approval for an over-the-counter version last summer after the Supreme Court's ruling the overturned Roe v. Wade, expects to start shipping the mini pill early next year.

In May, Ireland-based Perrigo, a leading provider of consumer self-care products, gained a key recommendation from U.S. regulatory advisors, which paved the way for Opill to get clearance to be sold without a prescription. The FDA is not required to follow the advisers' recommendations, but often does.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.